Image-Based Biomarker Estimation Through Tissue Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostate cancer screening methods, such as PSA tests and MRI examinations, fail to accurately identify patients with high or low biomarker levels, leading to unnecessary medical interventions or delayed diagnosis, due to their limitations in sensitivity and selectivity.
Innovation Solution
A method that processes medical images to identify tissue types within a region of interest, associates each type with biomarker production, and calculates the total biomarker production, incorporating clinical and patient data to provide a more accurate estimation of biomarker levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PSA test is used for initial screening, then early disease detection is improved, but overdiagnosis and unnecessary medical interventions occur
Solution Approach 1:
The patent combines PSA biomarker levels with MRI imaging data to create a composite risk assessment model. This integration allows for more accurate differentiation between clinically significant and insignificant prostate cancer cases, reducing overdiagnosis while maintaining early detection capabilities.
Solution Approach 2:
The patent introduces an intermediate risk stratification step between PSA testing and biopsy/MRI procedures. By categorizing patients into risk groups based on combined biomarker and imaging features, the system acts as a mediator that filters out low-risk cases before they undergo invasive procedures.
2Ease of manufacture
If PSA test is used for initial screening, then low cost and simple sampling are achieved, but sensitivity and selectivity are insufficient
Solution Approach 1:
The patent segments the patient population into different risk categories based on PSA levels, MRI findings, and other clinical features. This segmentation allows the system to apply different levels of diagnostic intensity to different groups, improving overall accuracy while maintaining simplicity for low-risk patients.
Solution Approach 2:
The patent adds another dimension (imaging modality) to the traditional single-dimension (PSA level) assessment. By incorporating MRI features alongside biomarker data, the system transforms a one-dimensional screening approach into a multi-dimensional evaluation, significantly improving sensitivity and selectivity.
3Measurement precision
If MRI and biopsy methods are used to identify cancer, then detection capability is improved, but false reassurance occurs in low PSA cases
Solution Approach 1:
The patent implements a feedback mechanism where the estimated biomarker production from imaged tissues is compared against the actual measured biomarker level. This feedback loop allows the system to identify discrepancies that may indicate missed diagnoses, preventing false reassurance in low PSA cases by flagging them for further investigation.
Data Source
AI summary
According to the invention there is provided a method of estimating an amount of at least one biomarker for a subject, based on an image of the subject imaged by a medical imaging method, the method comprising: processing the image to identify at least one tissue type within a region of interest of the image and determining an amount of each identified tissue type; associating each identified tissue type with a measure of biomarker production; calculating a total amount of biomarker production for the identified tissue types.